{"id":333572,"date":"2026-10-30T14:59:29","date_gmt":"2026-10-30T09:29:29","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=333572"},"modified":"2026-10-30T14:59:29","modified_gmt":"2026-10-30T09:29:29","slug":"pharma-excipients-and-food-ingredients-maker-respiratory-medicines-company-and-fluorospecialty-chemicals-group-stocks-roadmap-trailmap-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/pharma-excipients-and-food-ingredients-maker-respiratory-medicines-company-and-fluorospecialty-chemicals-group-stocks-roadmap-trailmap-list\/","title":{"rendered":"3 Pharma Excipients and Food Ingredients Maker, Respiratory Medicines Company and Fluorospecialty Chemicals Group Stocks With a Strong Future Roadmap: Sudeep Pharma, Cipla and SRF"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Sudeep Pharma, Cipla and SRF: ROE of 11.3% to 19.6% and FY22 to FY26 revenue CAGR of 6.1% to 17.6%. Prices as of 29 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three excipient, respiratory drug and fluorine stocks to watch are Sudeep Pharma, Cipla and SRF. Their return on equity ranges from 11.3% to 19.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.1% to 17.6%. Sudeep Pharma leads on both return on equity at 19.6% and revenue growth at 17.6% a year. Prices are based on the 29 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Excipient, respiratory drug and fluorine stocks offer a focused view of a sector where demand keeps widening. Sudeep Pharma, Cipla and SRF cover a pharma excipients and food ingredients maker, a respiratory medicines company and a fluorospecialty chemicals group.<\/p>\n<p>This list covers three excipient, respiratory drug and fluorine stocks with complete current figures: Sudeep Pharma, Cipla and SRF. Every figure comes from the latest reported financials and the 29 October 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=pharma-excipients-and-food-ingredients-maker-respiratory-medicines-company-and-fluorospecialty-chemicals-group-stocks-roadmap-trailmap-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/pharma-excipients-and-food-ingredients-maker-respiratory-medicines-company-and-fluorospecialty-chemicals-group-stocks-roadmap-trailmap-list\/#What_Are_Excipient_Respiratory_Drug_and_Fluorine_Stocks\" title=\"What Are Excipient, Respiratory Drug and Fluorine Stocks?\">What Are Excipient, Respiratory Drug and Fluorine Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/pharma-excipients-and-food-ingredients-maker-respiratory-medicines-company-and-fluorospecialty-chemicals-group-stocks-roadmap-trailmap-list\/#Excipient_Respiratory_Drug_and_Fluorine_Stocks_at_a_Glance\" title=\"Excipient, Respiratory Drug and Fluorine Stocks at a Glance\">Excipient, Respiratory Drug and Fluorine Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/pharma-excipients-and-food-ingredients-maker-respiratory-medicines-company-and-fluorospecialty-chemicals-group-stocks-roadmap-trailmap-list\/#Why_Do_Excipient_Respiratory_Drug_and_Fluorine_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Excipient, Respiratory Drug and Fluorine Stocks Have a Strong Roadmap in India?\">Why Do Excipient, Respiratory Drug and Fluorine Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/pharma-excipients-and-food-ingredients-maker-respiratory-medicines-company-and-fluorospecialty-chemicals-group-stocks-roadmap-trailmap-list\/#Why_Sudeep_Pharma_Features_Among_These_Excipient_Respiratory_Drug_and_Fluorine_Stocks\" title=\"Why Sudeep Pharma Features Among These Excipient, Respiratory Drug and Fluorine Stocks\">Why Sudeep Pharma Features Among These Excipient, Respiratory Drug and Fluorine Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/pharma-excipients-and-food-ingredients-maker-respiratory-medicines-company-and-fluorospecialty-chemicals-group-stocks-roadmap-trailmap-list\/#Why_Cipla_Features_Among_These_Excipient_Respiratory_Drug_and_Fluorine_Stocks\" title=\"Why Cipla Features Among These Excipient, Respiratory Drug and Fluorine Stocks\">Why Cipla Features Among These Excipient, Respiratory Drug and Fluorine Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/pharma-excipients-and-food-ingredients-maker-respiratory-medicines-company-and-fluorospecialty-chemicals-group-stocks-roadmap-trailmap-list\/#Why_SRF_Features_Among_These_Excipient_Respiratory_Drug_and_Fluorine_Stocks\" title=\"Why SRF Features Among These Excipient, Respiratory Drug and Fluorine Stocks\">Why SRF Features Among These Excipient, Respiratory Drug and Fluorine Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/pharma-excipients-and-food-ingredients-maker-respiratory-medicines-company-and-fluorospecialty-chemicals-group-stocks-roadmap-trailmap-list\/#Sudeep_Pharma_vs_Cipla_vs_SRF_on_Key_Financials\" title=\"Sudeep Pharma vs Cipla vs SRF on Key Financials\">Sudeep Pharma vs Cipla vs SRF on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/pharma-excipients-and-food-ingredients-maker-respiratory-medicines-company-and-fluorospecialty-chemicals-group-stocks-roadmap-trailmap-list\/#Key_Risks_to_Check_Before_Investing_in_Excipient_Respiratory_Drug_and_Fluorine_Stocks\" title=\"Key Risks to Check Before Investing in Excipient, Respiratory Drug and Fluorine Stocks\">Key Risks to Check Before Investing in Excipient, Respiratory Drug and Fluorine Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/pharma-excipients-and-food-ingredients-maker-respiratory-medicines-company-and-fluorospecialty-chemicals-group-stocks-roadmap-trailmap-list\/#Final_Thoughts_on_Excipient_Respiratory_Drug_and_Fluorine_Stocks\" title=\"Final Thoughts on Excipient, Respiratory Drug and Fluorine Stocks\">Final Thoughts on Excipient, Respiratory Drug and Fluorine Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/pharma-excipients-and-food-ingredients-maker-respiratory-medicines-company-and-fluorospecialty-chemicals-group-stocks-roadmap-trailmap-list\/#What_are_excipient_respiratory_drug_and_fluorine_stocks\" title=\"What are excipient, respiratory drug and fluorine stocks?\">What are excipient, respiratory drug and fluorine stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/pharma-excipients-and-food-ingredients-maker-respiratory-medicines-company-and-fluorospecialty-chemicals-group-stocks-roadmap-trailmap-list\/#Which_excipient_respiratory_drug_and_fluorine_stocks_are_covered_in_this_list\" title=\"Which excipient, respiratory drug and fluorine stocks are covered in this list?\">Which excipient, respiratory drug and fluorine stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/pharma-excipients-and-food-ingredients-maker-respiratory-medicines-company-and-fluorospecialty-chemicals-group-stocks-roadmap-trailmap-list\/#Why_do_excipient_respiratory_drug_and_fluorine_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do excipient, respiratory drug and fluorine stocks have a strong future roadmap in India?\">Why do excipient, respiratory drug and fluorine stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/pharma-excipients-and-food-ingredients-maker-respiratory-medicines-company-and-fluorospecialty-chemicals-group-stocks-roadmap-trailmap-list\/#How_has_Sudeep_Pharma_performed_financially\" title=\"How has Sudeep Pharma performed financially?\">How has Sudeep Pharma performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/pharma-excipients-and-food-ingredients-maker-respiratory-medicines-company-and-fluorospecialty-chemicals-group-stocks-roadmap-trailmap-list\/#How_has_Cipla_performed_financially\" title=\"How has Cipla performed financially?\">How has Cipla performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/pharma-excipients-and-food-ingredients-maker-respiratory-medicines-company-and-fluorospecialty-chemicals-group-stocks-roadmap-trailmap-list\/#How_has_SRF_performed_financially\" title=\"How has SRF performed financially?\">How has SRF performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/pharma-excipients-and-food-ingredients-maker-respiratory-medicines-company-and-fluorospecialty-chemicals-group-stocks-roadmap-trailmap-list\/#What_risks_should_investors_check_before_buying_excipient_respiratory_drug_and_fluorine_stocks\" title=\"What risks should investors check before buying excipient, respiratory drug and fluorine stocks?\">What risks should investors check before buying excipient, respiratory drug and fluorine stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/pharma-excipients-and-food-ingredients-maker-respiratory-medicines-company-and-fluorospecialty-chemicals-group-stocks-roadmap-trailmap-list\/#Is_this_list_of_excipient_respiratory_drug_and_fluorine_stocks_investment_advice\" title=\"Is this list of excipient, respiratory drug and fluorine stocks investment advice?\">Is this list of excipient, respiratory drug and fluorine stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Excipient_Respiratory_Drug_and_Fluorine_Stocks\"><\/span><strong>What Are Excipient, Respiratory Drug and Fluorine Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Excipient, respiratory drug and fluorine stocks are listed companies that make excipients and nutritional additives for drug and food makers, sell respiratory and chronic care medicines and produce refrigerant gases, fluorospecialty chemicals and packaging films. Their earnings depend on export orders, approvals and product mix.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Excipient_Respiratory_Drug_and_Fluorine_Stocks_at_a_Glance\"><\/span><strong>Excipient, Respiratory Drug and Fluorine Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/sudeepphrm\/sudeep-pharma-ltd-share-price-today\">Sudeep Pharma<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,130.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11,352<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">61.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">35.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.17<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/cipla\/cipla-ltd-share-price-today\">Cipla<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,358<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">107,528<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">32.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.02<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/srf\/srf-ltd-share-price-today\">SRF<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,358.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">69,274<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">30.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">33.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.35<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Cipla and SRF trade at a P\/E below the industry P\/E, while Sudeep Pharma trades above it, which reflects the growth the market already expects. Readers comparing excipient, respiratory drug and fluorine stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Excipient_Respiratory_Drug_and_Fluorine_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Excipient, Respiratory Drug and Fluorine Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Excipient, respiratory drug and fluorine stocks have a strong roadmap in India because global demand for nutrition and fortification products, steady medicine needs and wider use of specialty chemicals keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Nutrition demand.<\/strong> Fortified foods need specialty ingredients.<\/li>\n<li><strong>Respiratory care.<\/strong> Chronic conditions bring repeat prescriptions.<\/li>\n<li><strong>Specialty chemistry.<\/strong> Fluorochemicals serve many end uses.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Sudeep_Pharma_Features_Among_These_Excipient_Respiratory_Drug_and_Fluorine_Stocks\"><\/span><strong>Why Sudeep Pharma Features Among These Excipient, Respiratory Drug and Fluorine Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the excipient, respiratory drug and fluorine stocks on this list, Sudeep Pharma makes pharmaceutical excipients, food ingredients and nutritional additives such as minerals and fortification products for domestic and global customers.<\/p>\n<p>Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%.<\/p>\n<p>In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P\/E of 61.8, above the industry P\/E of 35.1.<\/p>\n<p><strong>Roadmap:<\/strong> Excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.<\/p>\n<p><strong>What to watch:<\/strong> Check capacity expansion progress and export revenue growth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Cipla_Features_Among_These_Excipient_Respiratory_Drug_and_Fluorine_Stocks\"><\/span><strong>Why Cipla Features Among These Excipient, Respiratory Drug and Fluorine Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the nutrition and pharma exporters shares on this list, Cipla is a Mumbai-based pharmaceutical company with strengths in respiratory medicines, anti-infectives and chronic therapies. It sells branded and generic products in India, South Africa, the United States and other markets.<\/p>\n<p>In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%.<\/p>\n<p>Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P\/E of 32.0, below the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.<\/p>\n<p><strong>What to watch:<\/strong> Follow new product launches in the United States and the growth of key domestic brands.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_SRF_Features_Among_These_Excipient_Respiratory_Drug_and_Fluorine_Stocks\"><\/span><strong>Why SRF Features Among These Excipient, Respiratory Drug and Fluorine Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, SRF is a diversified chemicals and materials company with fluorospecialty chemicals, refrigerant gases, packaging films and technical textiles, with customers in India and overseas.<\/p>\n<p>The company has a return on equity of 14.9%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 69,274 crore. The stock trades at a P\/E of 30.4, below the industry P\/E of 33.9.<\/p>\n<p>Revenue rose from Rs 12,549 crore in FY22 to Rs 15,894 crore in FY26, a compound annual growth rate of 6.1%. Net profit grew from Rs 1,336 crore in FY24 to Rs 1,835 crore in FY26, which works out to a compound annual growth rate of 17.2%.<\/p>\n<p><strong>Roadmap:<\/strong> The company is expanding in specialty chemicals and refrigerant gases while its packaging films and technical textiles businesses add scale. A mix of segments spreads earnings.<\/p>\n<p><strong>What to watch:<\/strong> Track specialty chemicals growth, refrigerant gas demand and capacity additions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Sudeep_Pharma_vs_Cipla_vs_SRF_on_Key_Financials\"><\/span><strong>Sudeep Pharma vs Cipla vs SRF on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three excipient, respiratory drug and fluorine stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Sudeep Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">350<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">671<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.6%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">174<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">26.0%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Cipla<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22,044<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">29,045<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,870<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.3%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">SRF<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12,549<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15,894<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">6.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,835<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.5%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Sudeep Pharma posts the highest return on equity in this group at 19.6%. Cipla has the largest FY26 revenue at Rs 29,045 crore, and Sudeep Pharma shows the fastest revenue growth with a 17.6% compound annual rate. A useful habit with excipient, respiratory drug and fluorine stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Excipient_Respiratory_Drug_and_Fluorine_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Excipient, Respiratory Drug and Fluorine Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these excipient, respiratory drug and fluorine stocks, the main points are:<\/p>\n<ul>\n<li><strong>Regulatory approvals.<\/strong> Plant inspections and approvals can affect supplies.<\/li>\n<li><strong>Raw material and energy costs.<\/strong> Input prices can move margins in chemicals.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter excipient, respiratory drug and fluorine stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Excipient_Respiratory_Drug_and_Fluorine_Stocks\"><\/span><strong>Final Thoughts on Excipient, Respiratory Drug and Fluorine Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Excipient, respiratory drug and fluorine stocks reward patient research into demand, execution and financial strength. Sudeep Pharma, Cipla and SRF each have a clear plan to grow. Based on the 29 October 2026 close, Sudeep Pharma trades at Rs 1,130.1, Cipla at Rs 1,358 and SRF at Rs 2,358.6.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track excipient, respiratory drug and fluorine stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_excipient_respiratory_drug_and_fluorine_stocks\"><\/span><strong>What are excipient, respiratory drug and fluorine stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Excipient, respiratory drug and fluorine stocks are listed companies that make excipients and nutritional additives for drug and food makers, sell respiratory and chronic care medicines and produce refrigerant gases, fluorospecialty chemicals and packaging films. Their earnings depend on export orders, approvals and product mix. This list looks at three of them, Sudeep Pharma, Cipla and SRF, using reported FY22 to FY26 financials and the 29 October 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_excipient_respiratory_drug_and_fluorine_stocks_are_covered_in_this_list\"><\/span><strong>Which excipient, respiratory drug and fluorine stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Sudeep Pharma, Cipla and SRF. Based on the 29 October 2026 close, Sudeep Pharma traded at Rs 1,130.1, Cipla at Rs 1,358 and SRF at Rs 2,358.6. Their return on equity ranges from 11.3% to 19.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.1% to 17.6%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_excipient_respiratory_drug_and_fluorine_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do excipient, respiratory drug and fluorine stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Excipient, respiratory drug and fluorine stocks have a strong roadmap in India because global demand for nutrition and fortification products, steady medicine needs and wider use of specialty chemicals keep widening the market for these companies. The main drivers are as follows. Nutrition demand. Fortified foods need specialty ingredients. Respiratory care. Chronic conditions bring repeat prescriptions. Specialty chemistry. Fluorochemicals serve many end uses. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Sudeep_Pharma_performed_financially\"><\/span><strong>How has Sudeep Pharma performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%. In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P\/E of 61.8, above the industry P\/E of 35.1. Looking ahead, excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Cipla_performed_financially\"><\/span><strong>How has Cipla performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P\/E of 32.0, below the industry P\/E of 36.0. Looking ahead, the company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_SRF_performed_financially\"><\/span><strong>How has SRF performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 12,549 crore in FY22 to Rs 15,894 crore in FY26, a compound annual growth rate of 6.1%. Net profit grew from Rs 1,336 crore in FY24 to Rs 1,835 crore in FY26, which works out to a compound annual growth rate of 17.2%. The company has a return on equity of 14.9%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 69,274 crore. The stock trades at a P\/E of 30.4, below the industry P\/E of 33.9. Looking ahead, the company is expanding in specialty chemicals and refrigerant gases while its packaging films and technical textiles businesses add scale. A mix of segments spreads earnings.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_excipient_respiratory_drug_and_fluorine_stocks\"><\/span><strong>What risks should investors check before buying excipient, respiratory drug and fluorine stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying excipient, respiratory drug and fluorine stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Raw material and energy costs. Input prices can move margins in chemicals. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_excipient_respiratory_drug_and_fluorine_stocks_investment_advice\"><\/span><strong>Is this list of excipient, respiratory drug and fluorine stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 29 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are excipient, respiratory drug and fluorine stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Excipient, respiratory drug and fluorine stocks are listed companies that make excipients and nutritional additives for drug and food makers, sell respiratory and chronic care medicines and produce refrigerant gases, fluorospecialty chemicals and packaging films. Their earnings depend on export orders, approvals and product mix. This list looks at three of them, Sudeep Pharma, Cipla and SRF, using reported FY22 to FY26 financials and the 29 October 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which excipient, respiratory drug and fluorine stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Sudeep Pharma, Cipla and SRF. Based on the 29 October 2026 close, Sudeep Pharma traded at Rs 1,130.1, Cipla at Rs 1,358 and SRF at Rs 2,358.6. Their return on equity ranges from 11.3% to 19.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.1% to 17.6%.\"}},{\"@type\":\"Question\",\"name\":\"Why do excipient, respiratory drug and fluorine stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Excipient, respiratory drug and fluorine stocks have a strong roadmap in India because global demand for nutrition and fortification products, steady medicine needs and wider use of specialty chemicals keep widening the market for these companies. The main drivers are as follows. Nutrition demand. Fortified foods need specialty ingredients. Respiratory care. Chronic conditions bring repeat prescriptions. Specialty chemistry. Fluorochemicals serve many end uses. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Sudeep Pharma performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%. In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P\/E of 61.8, above the industry P\/E of 35.1. Looking ahead, excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.\"}},{\"@type\":\"Question\",\"name\":\"How has Cipla performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P\/E of 32.0, below the industry P\/E of 36.0. Looking ahead, the company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.\"}},{\"@type\":\"Question\",\"name\":\"How has SRF performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 12,549 crore in FY22 to Rs 15,894 crore in FY26, a compound annual growth rate of 6.1%. Net profit grew from Rs 1,336 crore in FY24 to Rs 1,835 crore in FY26, which works out to a compound annual growth rate of 17.2%. The company has a return on equity of 14.9%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 69,274 crore. The stock trades at a P\/E of 30.4, below the industry P\/E of 33.9. Looking ahead, the company is expanding in specialty chemicals and refrigerant gases while its packaging films and technical textiles businesses add scale. A mix of segments spreads earnings.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying excipient, respiratory drug and fluorine stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying excipient, respiratory drug and fluorine stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Raw material and energy costs. Input prices can move margins in chemicals. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of excipient, respiratory drug and fluorine stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 29 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Excipient, Respiratory Drug and Fluorine Stocks with a strong future roadmap: Sudeep Pharma, Cipla and SRF. Compare price, valuation, return on equity and revenue growth as of 28 October 2026.<\/p>\n","protected":false},"author":34,"featured_media":333571,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3803,3792,18639,18642,18641,18640,681,6884],"class_list":["post-333572","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-stocks","tag-cipla","tag-excipient","tag-ingredient-and-medicine-makers","tag-nutrition-and-pharma-exporters-shares","tag-respiratory-drug-and-fluorine-stocks","tag-srf","tag-sudeep-pharma"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["333571"],"rank_math_title":["Excipient, Respiratory Pharma and Fluorochemical Stocks"],"rank_math_description":["Compare 3 excipient, respiratory drug and fluorine stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 28 Oct 2026."],"rank_math_focus_keyword":["excipient, respiratory drug and fluorine stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/3-pharma-excipients-and-food-ingredients-maker-respiratory-medicines-company-and.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/333572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=333572"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/333572\/revisions"}],"predecessor-version":[{"id":333573,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/333572\/revisions\/333573"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/333571"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=333572"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=333572"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=333572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}